Cabrera-Rode E, Diaz-Horta O, Fernandez L E, Carr A, Marquina G, Valiente O, Gonzalez-Suarez R M, Uriarte A
National Institute of Endocrinology, Havana, Cuba.
Autoimmunity. 1995;20(3):145-51. doi: 10.3109/08916939508993345.
It has been recently suggested that pancreatic glycolipidic extracts and acidic glycolipid fractions are able to block the binding of ICA to frozen sections of human pancreas. We study the prevalence of blocking effect by the upper-phase from human pancreatic glycolipid extracts (PGE) in thirty-eight sera ICA positive from seventeen IDDM patients and twenty-one first relatives of type 1 diabetics. Total inhibition was found in 82% and 76% insulin dependent diabetes mellitus patients and first relatives of type 1 diabetics respectively. Partial and no inhibition of ICA+ sera was seen in 6%, 12% of type 1 diabetics and 19%, 5% of the first degree relatives of type 1 diabetics respectively. Our study suggests that there is heterogeneity of cytoplasmatic islet cell antibodies and that glycolipids are the major autoantigen of ICA.
最近有人提出，胰腺糖脂提取物和酸性糖脂组分能够阻断胰岛细胞抗体（ICA）与人类胰腺冰冻切片的结合。我们研究了人类胰腺糖脂提取物（PGE）上层相在17例胰岛素依赖型糖尿病（IDDM）患者的38份血清ICA阳性样本以及21例1型糖尿病患者的一级亲属样本中阻断作用的发生率。分别在82%的IDDM患者和76%的1型糖尿病患者一级亲属中发现了完全抑制作用。在1型糖尿病患者中，分别有6%、12%的ICA阳性血清出现部分抑制和无抑制现象；在1型糖尿病患者的一级亲属中，这一比例分别为19%、5%。我们的研究表明，细胞质胰岛细胞抗体存在异质性，并且糖脂是ICA的主要自身抗原。
